Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor J Cee

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1)Brian A Lanman, Victor J Cee, Srinivasa R Cheruku, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|January 10, 2019
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological MalignanciesHui-Ling Wang, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Journal of Medicinal Chemistry|February 11, 2025
Identification of Structurally Novel KRAS<sup>G12C</sup> Inhibitors through Covalent DNA-Encoded Library ScreeningDavid Huang, Francesco Manoni, Zhen Sun, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1)Brian A Lanman, Victor J Cee, Srinivasa R Cheruku, et al.
Journal of Medicinal Chemistry|June 11, 2016
Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase InhibitorsLiping H Pettus, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|January 10, 2019
Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological MalignanciesHui-Ling Wang, Kristin L Andrews, Shon K Booker, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Nature|November 1, 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityJude Canon, Karen Rex, Anne Y Saiki, et al.
Journal of Medicinal Chemistry|February 11, 2025
Identification of Structurally Novel KRAS<sup>G12C</sup> Inhibitors through Covalent DNA-Encoded Library ScreeningDavid Huang, Francesco Manoni, Zhen Sun, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Pageof 4